Reverse Phase Protein Microarray Technology: Advances into the Clinical Research Arena - Proteomic and Metabolomic Approaches to Biomarker Discovery - page 339

CHAPTER
22

Reverse Phase Protein Microarray
Technology: Advances into the Clinical
Research Arena

Emanuel F. Petricoin III 1 , Brian Leyland-Jones 2 , Julie Wulfkuhle 1 ,
Marielena Pierobon 1 , Claudius Mueller 1 , Virginia Espina 1 ,
Lance A. Liotta 1
1 George Mason University, Center for Applied Proteomics and Molecular Medicine,
Manassas, VA, USA,

2 Edith Sanford Breast Cancer Initiative, Sioux Falls, SD, USA

OUTLINE

Introduction 350 Prevention of Invasive Breast Neoplasia

by Chloroquine (PINC) Trial 354

Origin of RPMA Technology 350

Phase II Trial of Trastuzumab and/or
Lapatinib Plus Chemotherapy for Her2 RPMA in the Molecular Oncology Clinic 351

Protein Stability and Preanalytical Variability 351
RPMA Has Graduated to Use in Cancer
Clinical Trial Research 352
I-SPY 1 and I-SPY 2 Breast Cancer Trials 353
New Individualized Therapy Trial for
Metastatic Colorectal Cancer (NITMEC)
Trial

þ

355

Breast Cancer

Phase II Trial of Radiation, Cisplatin, and
Panitumumab in Head and Neck Cancer 355
Validation of Mass SpectrometryeDiscovered
Candidate Biomarkers by RPMA 356

353 Conclusions and Vision for the Future 356

SIDE-OUT Metastatic Breast Cancer
Personalized Therapy Trial

References 357

354